Cardiovascular risks with prostate cancer hormonal treatment: rationale for a department of oncocardiology;Risques cardiovasculaires avec les hormonothérapies pour cancer de la prostate : rationnel pour une unité oncocardiologique

Cancer/Radiotherapie

Volumn 20, Issue 5, 2016, Pages 405-410

  Latorzeff, I ^a   Ploussard, G ^b   Guillotreau, J ^a   Jonca, F ^c   Labarthe, P ^d   Rollin, G ^e   Beauval, J B ^f   Pathak, A ^a  

^a CLINIQUE PASTEUR   (France)

^b Service d'urologie   (France)

^c Service d'urologie   (France)

^d Service d'Urologie CH René Dubos   (France)

^e Service d'urologie   (France)

^f CHU RANGUEIL   (France)

Author keywords

Cardiovascular risk; Hormonal treatment; Prostate cancer; Unit of oncocardiology

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTIANDROGEN;

CANCER HORMONE THERAPY; CARDIOLOGIST; CARDIOVASCULAR RISK; HUMAN; MALE; ONCOLOGIST; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; UROLOGIST; CARDIOLOGY; CARDIOTOXICITY; ONCOLOGY; PATIENT CARE; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

ANDROGEN ANTAGONISTS; CARDIOLOGISTS; CARDIOLOGY; CARDIOTOXICITY; HUMANS; MALE; MEDICAL ONCOLOGY; ONCOLOGISTS; PATIENT CARE TEAM; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84990997759     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2016.02.015     Document Type: Short Survey

References (44)

1. [1] Traish, A.M., Abdou, R., Kypreos, K.E., Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol 51 (2009), 303–313.
2. [2] Han, Y., Fu, L., Sun, W., Cao, J., Xie, R., Zhou, P., et al. Neuroprotective effects of testosterone upon cardiac sympathetic function in rats with induced heart failure. Eur J Pharmacol 619 (2009), 68–74.
3. [3] Jankowska, E.A., Filippatos, G., Ponikowska, B., Borodulin-Nadzieja, L., Anker, S.D., Banasiak, W., et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail 15 (2009), 442–450.
4. [4] Chen, H.F., Jeung, E.B., Stephenson, M., Leung, P.C., Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 84 (1999), 743–750.
5. [5] Tanriverdi, F., Gonzalez-Martinez, D., Hu, Y., Kelestimur, F., Bouloux, P.M., GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 142 (2005), 103–110.
6. [6] Hopmans, S.N., Duivenvoorden, W.C., Werstuck, G.H., Klotz, L., Pinthus, J.H., GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol 32 (2014), 1126–1134.
7. [7] Isbarn, H., Boccon-Gibod, L., Carroll, P.R., Montorsi, F., Schulman, C., Smith, M.R., et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 55 (2009), 62–75.
8. [8] Taylor, L.G., Canfield, S.E., Du, X.L., Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115 (2009), 2388–2399.
9. [9] Shao, Y.H., Demissie, K., Shih, W., Mehta, A.R., Stein, M.N., Roberts, C.B., et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 101 (2009), 1280–1283.
10. [10] Levine, G.N., D'Amico, A.V., Berger, P., Clark, P.E., Eckel, R.H., Keating, N.L., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121 (2010), 833–840.
11. [11] Bechis, S.K., Carroll, P.R., Cooperberg, M.R., Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 29 (2011), 235–241.
12. [12] Mottet, N., Peneau, M., Mazeron, J.J., Molinie, V., Richaud, P., Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 62 (2012), 213–219.
13. [13] Widmark, A., Klepp, O., Solberg, A., Damber, J.E., Angelsen, A., Fransson, P., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373 (2009), 301–308 [Erratum in: Lancet 2009;373:1174].
14. [14] Warde, P., Mason, M., Ding, K., Kirkbride, P., Brundage, M., Cowan, R., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378 (2011), 2104–2111.
15. [15] D'Amico, A.V., Chen, M.H., Renshaw, A., Loffredo, M., Kantoff, P.W., Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 314 (2015), 1291–1293.
16. [16] D'Amico, A.V., Chen, M.H., Renshaw, A.A., Loffredo, M., Kantoff, P.W., Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008), 289–295.
17. [17] Morgans, A.K., Fan, K.H., Koyama, T., Albertsen, P.C., Goodman, M., Hamilton, A.S., et al. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol 193 (2015), 1226–1231.
18. [18] Saylor, P.J., Smith, M.R., Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 189 (2013), S34–S42.
19. [19] Saigal, C.S., Gore, J.L., Krupski, T.L., Hanley, J., Schonlau, M., Litwin, M.S., Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007), 1493–1500.
20. [20] Keating, N.L., O'Malley, A.J., Smith, M.R., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006), 4448–4456.
21. [21] Keating, N.L., O'Malley, A.J., Freedland, S.J., Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102 (2010), 39–46.
22. [22] Gandaglia, G., Sun, M., Popa, I., Schiffmann, J., Abdollah, F., Trinh, Q.D., et al. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. BJU Int 114 (2014), E82–E89.
23. [23] Bosco, C., Bosnyak, Z., Malmberg, A., Adolfsson, J., Keating, N.L., Van Hemelrijck, M., Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 68 (2015), 386–396.
24. [24] Zhao, J., Zhu, S., Sun, L., Meng, F., Zhao, L., Zhao, Y., et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One, 9, 2014, e107516.
25. [25] Roach, M., Bae, K., Speight, J., Wolkov, H.B., Rubin, P., Lee, R.J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26 (2008), 585–591.
26. [26] Bolla, M., de Reijke, T.M., Van Tienhoven, G., Van den Bergh, A.C., Oddens, J., Poortmans, P.M., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360 (2009), 2516–2527.
27. [27] Efstathiou, J.A., Bae, K., Shipley, W.U., Hanks, G.E., Pilepich, M.V., Sandler, H.M., et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54 (2008), 816–823.
28. [28] Efstathiou, J.A., Bae, K., Shipley, W.U., Hanks, G.E., Pilepich, M.V., Sandler, H.M., et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27 (2008), 92–99.
29. [29] Nguyen, P.L., Je, Y., Schutz, F.A., Hoffman, K.E., Hu, J.C., Parekh, A., et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306 (2011), 2359–2366.
30. [30] Kim, J., Vaid, M., Tyldesley, S., Woods, R., Pickles, T., Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia Cancer Agency. Int J Radiat Oncol Biol Phys 80 (2011), 742–750.
31. [31] Nanda, A., Chen, M.H., Moran, B.J., Braccioforte, M.H., D'Amico, A.V., Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys 85 (2013), e209–e215, 10.1016/j.ijrobp.2012.11.039 [Epub 2013 Jan 16].
32. [32] Nguyen, P.L., Chen, M.H., Goldhaber, S.Z., Martin, N.E., Beard, C.J., Dosoretz, D.E., et al. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer 117 (2011), 406–413.
33. [33] Sheperd, J., FDA drug safety podcast for healthcare professionals: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases [podcast 10/20/2010]. 2010, Food and Drug Administration, Silver Spring MD [Disponible en ligne à l'adresse : http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm230464.htm].
34. [34] O'Farrell, S., Garmo, H., Holmberg, L., Adolfsson, J., Stattin, P., Van Hemelrijck, M., Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33 (2015), 1243–1251.
35. [35] Klotz, L., Boccon-Gibod, L., Shore, N.D., Andreou, C., Persson, B.E., Cantor, P., et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102 (2008), 1531–1538.
36. [36] Van Poppel, H., Klotz, L., Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 19 (2012), 594–601.
37. [37] Ben-Josef, E., Yang, S.Y., Ji, T.H., Bidart, J.M., Garde, S.V., Chopra, D.P., et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 161 (1999), 970–976.
38. [38] Radu, A., Pichon, C., Camparo, P., Antoine, M., Allory, Y., Couvelard, A., et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363 (2010), 1621–1630.
39. [39] Klotz, L., Miller, K., Crawford, E.D., Shore, N., Tombal, B., Karup, C., et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol 66 (2014), 1101–1108.
40. [40] Smith, M.R., Klotz, L., van der Meulen, E., Colli, E., Tankó, L.B., Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 186 (2011), 1835–1842.
41. [41] Albertsen, P.C., Klotz, L., Tombal, B., Grady, J., Olesen, T.K., Nilsson, J., Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65 (2014), 565–573.
42. [42] Salomon, L., Bastide, C., Beuzeboc, P., Cormier, L., Fromont, G., Hennequin, C., et al. Recommandations en onco-urologie 2013 du CCAFU: cancer de la prostate. Prog Urol 23 (2013), S69–S101.
43. [43] Gardner, J.R., Livingston, P.M., Fraser, S.F., Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 32 (2014), 335–346.
44. [44] Quero, L., Hennequin, C., Medical treatment for biochemical relapse after radiotherapy. Cancer Radiother 18 (2014), 540–544.